Applied DNA Sciences, Inc.
25 Health Sciences Drive
Stony Brook
New York
11790
United States
Tel: 631-444-6861
Fax: 631-444-8848
Website: http://www.adnas.com/
387 articles about Applied DNA Sciences, Inc.
-
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
6/8/2023
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that it has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023.
-
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
5/11/2023
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the second quarter of fiscal 2023 ended March 31, 2023.
-
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
5/3/2023
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023.
-
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation
4/7/2023
Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website.
-
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
3/29/2023
Applied DNA Sciences, Inc. today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks.
-
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
3/22/2023
Applied DNA Sciences, Inc. announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has submitted a validation package to the New York State Department of Health in support of approval for a pharmacogenomics assay as a NYSDOH laboratory-developed test.
-
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
2/10/2023
Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the receipt of an up to $1.5 million award from New York State’s Empire State Development agency.
-
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
2/9/2023
Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022.
-
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
2/2/2023
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023.
-
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
1/5/2023
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development.
-
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
12/14/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.
-
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
12/12/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.
-
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
10/24/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today plans to establish a new, separate manufacturing facility to be located in Suffolk County, New York, for the enzymatic production of cGMP LinearDNA™ for use in genetic medicines.
-
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
10/10/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
-
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
9/30/2022
Applied DNA Sciences, Inc. today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a LinearDNA™-based vaccine candidate (the “vaccine candidate”) reduced infectious virus shedding and was protective against SARS-CoV-2 in a challenge trial in ferrets.
-
Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
9/8/2022
Applied DNA Sciences, Inc., a leader in polymerase chain reaction -based technologies, and the Cornell University College of Veterinary Medicine announced the signing of a research agreement to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications.
-
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
9/7/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time.
-
Applied DNA Launches Monkeypox Testing Service
9/6/2022
Applied DNA Sciences, Inc. announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.
-
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health
8/19/2022
Applied DNA Sciences, Inc. announced today that it has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT).
-
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
8/11/2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2022, ended June 30, 2022.